231 related articles for article (PubMed ID: 10646867)
1. High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer.
Anttila MA; Tammi RH; Tammi MI; Syrjänen KJ; Saarikoski SV; Kosma VM
Cancer Res; 2000 Jan; 60(1):150-5. PubMed ID: 10646867
[TBL] [Abstract][Full Text] [Related]
2. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan expression in differentiated thyroid carcinoma.
Böhm J; Niskanen L; Tammi R; Tammi M; Eskelinen M; Pirinen R; Hollmen S; Alhava E; Kosma VM
J Pathol; 2002 Feb; 196(2):180-5. PubMed ID: 11793369
[TBL] [Abstract][Full Text] [Related]
5. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.
Kayastha S; Freedman AN; Piver MS; Mukkamalla J; Romero-Guittierez M; Werness BA
Clin Cancer Res; 1999 May; 5(5):1073-6. PubMed ID: 10353740
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
Sillanpää S; Anttila M; Voutilainen K; Ropponen K; Turpeenniemi-Hujanen T; Puistola U; Tammi R; Tammi M; Sironen R; Saarikoski S; Kosma VM
Gynecol Oncol; 2007 Feb; 104(2):296-303. PubMed ID: 17034838
[TBL] [Abstract][Full Text] [Related]
7. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R
Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
[TBL] [Abstract][Full Text] [Related]
8. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis.
Pirinen R; Leinonen T; Böhm J; Johansson R; Ropponen K; Kumpulainen E; Kosma VM
Hum Pathol; 2005 Jan; 36(1):44-50. PubMed ID: 15712181
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
[TBL] [Abstract][Full Text] [Related]
10. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM
Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
[TBL] [Abstract][Full Text] [Related]
11. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
12. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis.
Voutilainen K; Anttila M; Sillanpää S; Tammi R; Tammi M; Saarikoski S; Kosma VM
Int J Cancer; 2003 Nov; 107(3):359-64. PubMed ID: 14506734
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
14. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan.
Tammi RH; Kultti A; Kosma VM; Pirinen R; Auvinen P; Tammi MI
Semin Cancer Biol; 2008 Aug; 18(4):288-95. PubMed ID: 18468453
[TBL] [Abstract][Full Text] [Related]
16. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
17. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
18. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
[TBL] [Abstract][Full Text] [Related]
19. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.
Jiang YP; Wu XH; Shi B; Wu WX; Yin GR
Gynecol Oncol; 2006 Oct; 103(1):226-33. PubMed ID: 16631235
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers.
Bao LH; Sakaguchi H; Fujimoto J; Tamaya T
J Biomed Sci; 2007 May; 14(3):373-81. PubMed ID: 17219251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
